Watson Pharmaceuticals, Inc. (NYSE: WPI) is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of branded pharmaceuticals focused on Urology, Gynecology and Nephrology (Medical).

 

 

 

In the U.S., the Watson portfolio includes RAPAFLO^®, GELNIQUE^®, TRELSTAR^® LA; TRELSTAR^® Depot; INFeD^® and Oxytrol^®. In addition, Watson markets the following brands under co-promotion agreements: AndroGel^®, with Solvay Pharmaceuticals, Inc., and Femring^®, with Warner Chilcott Limited. The Watson pipeline portfolio includes a number of products, including a six-month formulation of TRELSTAR^®, for the treatment of advanced prostate cancer which is currently under review by the FDA; URACYST^®, under development for cystitis; and a novel new oral contraceptive.

 

 

 

For press releases and other company information, visit the Watson Web site at http://www.watson.com.